50870-44-5Relevant academic research and scientific papers
CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE
-
Paragraph 00249; 00250; 00916; 00918; 001235; 001236, (2018/07/29)
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.
ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
-
Paragraph 0260; 0261; 0262; 0263, (2017/06/12)
A compound of formula (I): wherein the substituents are as defined in the description. Medicinal products containing the same which are useful in treating or preventing pathologies which are the result of activation of the RhoA/ROCK pathway and phosphorylation of the myosin light chain.
Structure-based approach to the development of potent and selective inhibitors of dihydrofolate reductase from Cryptosporidium
Bolstad, David B.,Bolstad, Erin S. D.,Frey, Kathleen M.,Wright, Dennis L.,Anderson, Amy C.
experimental part, p. 6839 - 6852 (2009/11/30)
Cryptosporidiosis is an emerging infectious disease that can be life-threatening in an immune-compromised individual and causes gastrointestinal distress lasting up to 2 weeks in an immune-competent individual. There are few therapeutics available for eff
